255 related articles for article (PubMed ID: 29989198)
1. HER2 immunohistochemistry in endometrial and ovarian clear cell carcinoma: discordance between antibodies and with in-situ hybridisation.
Koopman T; van der Vegt B; Dijkstra M; Bart J; Duiker E; Wisman GBA; de Bock GH; Hollema H
Histopathology; 2018 Nov; 73(5):852-863. PubMed ID: 29989198
[TBL] [Abstract][Full Text] [Related]
2. Analytical validation of human epidermal growth factor receptor 2 immunohistochemistry by the use of the A0485 antibody versus the 4B5 antibody and breast versus gastric scoring guidelines in ovarian clear cell carcinoma.
Lin SY; Wang YH; Hsu CY; Chen YJ; Lai CR; Hang JF
Histopathology; 2021 Nov; 79(5):758-767. PubMed ID: 34036622
[TBL] [Abstract][Full Text] [Related]
3. HER2 in gastric cancer: comparative analysis of three different antibodies using whole-tissue sections and tissue microarrays.
Abrahão-Machado LF; Jácome AA; Wohnrath DR; dos Santos JS; Carneseca EC; Fregnani JH; Scapulatempo-Neto C
World J Gastroenterol; 2013 Oct; 19(38):6438-46. PubMed ID: 24151362
[TBL] [Abstract][Full Text] [Related]
4. False positivity in HER2 testing of breast cancer: novel paths for approaching an old dilemma.
Nunes CB; Rocha RM; Buzelin MA; Balabram D; de Souza Foureaux F; Porto SS; Gobbi H
J Clin Pathol; 2013 Nov; 66(11):946-50. PubMed ID: 23867547
[TBL] [Abstract][Full Text] [Related]
5. Breast cancer HER2 equivocal cases: is there an alternative to FISH testing? A pilot study using two different antibodies sequentially.
Yosepovich A; Avivi C; Bar J; Polak-Charcon S; Mardoukh C; Barshack I
Isr Med Assoc J; 2010 Jun; 12(6):353-6. PubMed ID: 20928989
[TBL] [Abstract][Full Text] [Related]
6. Performance of HER2 DAKO HercepTest and Ventana 4B5 immunohistochemical assays on detecting HER2 gene-amplification in uterine serous carcinomas.
Navarro Sanchez JM; Finkelman BS; Tyburski H; Turner BM; Moisini I; Katerji H; Varghese S; Wang X; Schiffhauer LM; Chen JJ; Hicks DG; Zhang H
Hum Pathol; 2024 Jun; 148():51-59. PubMed ID: 38740270
[TBL] [Abstract][Full Text] [Related]
7. Comparison of Dako HercepTest and Ventana PATHWAY Anti-HER2 (4B5) Tests and Their Correlation With Fluorescent In Situ Hybridization in Breast Carcinoma.
Lucas E; Jabbar SB; Molberg K; Fang Y; Xie XJ; Blacketer S; Sahoo S
Appl Immunohistochem Mol Morphol; 2019 Jul; 27(6):403-409. PubMed ID: 31233398
[TBL] [Abstract][Full Text] [Related]
8. Comparison of HercepTest™ mAb pharmDx (Dako Omnis, GE001) with Ventana PATHWAY anti-HER-2/neu (4B5) in breast cancer: correlation with HER2 amplification and HER2 low status.
Rüschoff J; Friedrich M; Nagelmeier I; Kirchner M; Andresen LM; Salomon K; Portier B; Sredni ST; Schildhaus HU; Jasani B; Grzelinski M; Viale G
Virchows Arch; 2022 Nov; 481(5):685-694. PubMed ID: 35970977
[TBL] [Abstract][Full Text] [Related]
9. What is the added value of digital image analysis of HER2 immunohistochemistry in breast cancer in clinical practice? A study with multiple platforms.
Koopman T; Buikema HJ; Hollema H; de Bock GH; van der Vegt B
Histopathology; 2019 May; 74(6):917-924. PubMed ID: 30585668
[TBL] [Abstract][Full Text] [Related]
10. Determining sensitivity and specificity of HER2 testing in breast cancer using a tissue micro-array approach.
Dekker TJ; Borg ST; Hooijer GK; Meijer SL; Wesseling J; Boers JE; Schuuring E; Bart J; van Gorp J; Mesker WE; Kroep JR; Smit VT; van de Vijver MJ
Breast Cancer Res; 2012 Jun; 14(3):R93. PubMed ID: 22694844
[TBL] [Abstract][Full Text] [Related]
11. HER2 status in gastro-oesophageal adenocarcinomas assessed by two rabbit monoclonal antibodies (SP3 and 4B5) and two in situ hybridization methods (FISH and SISH).
Boers JE; Meeuwissen H; Methorst N
Histopathology; 2011 Feb; 58(3):383-94. PubMed ID: 21323962
[TBL] [Abstract][Full Text] [Related]
12. Performance of a HER2 testing algorithm specific for p53-abnormal endometrial cancer.
Vermij L; Singh N; Leon-Castillo A; Horeweg N; Oosting J; Carlson J; Smit V; Gilks B; Bosse T
Histopathology; 2021 Oct; 79(4):533-543. PubMed ID: 33835523
[TBL] [Abstract][Full Text] [Related]
13. SP3, a reliable alternative to HercepTest in determining HER-2/neu status in breast cancer patients.
D'Alfonso TM; Liu YF; Chen Z; Chen YB; Cimino-Mathews A; Shin SJ
J Clin Pathol; 2013 May; 66(5):409-14. PubMed ID: 23386665
[TBL] [Abstract][Full Text] [Related]
14. Immunohistochemical results of HER2/neu protein expression assessed by rabbit monoclonal antibodies SP3 and 4B5 in colorectal carcinomas.
Song Z; Deng Y; Zhuang K; Li A; Liu S
Int J Clin Exp Pathol; 2014; 7(7):4454-60. PubMed ID: 25120833
[TBL] [Abstract][Full Text] [Related]
15. IHC for Her2 with CBE356 antibody is a more accurate predictor of Her2 gene amplification by FISH than HercepTest in breast carcinoma.
Ainsworth R; Bartlett JM; Going JJ; Mallon EA; Forsyth A; Richmond J; Angerson W; Watters A; Dunne B
J Clin Pathol; 2005 Oct; 58(10):1086-90. PubMed ID: 16189156
[TBL] [Abstract][Full Text] [Related]
16. Comparative analysis of six different antibodies against Her2 including the novel rabbit monoclonal antibody (SP3) and chromogenic in situ hybridisation in breast carcinomas.
Nunes CB; Rocha RM; Reis-Filho JS; Lambros MB; Rocha GF; Sanches FS; Oliveira FN; Gobbi H
J Clin Pathol; 2008 Aug; 61(8):934-8. PubMed ID: 18474540
[TBL] [Abstract][Full Text] [Related]
17. A comparison study of HER2 protein overexpression and its gene status in breast cancer.
Md Pauzi SH; Saari HN; Roslan MR; Syed Khair Azman Jamalulil SNS; Tauan IS; Mohd Rusli FA; Aizuddin AN
Malays J Pathol; 2019 Aug; 41(2):133-138. PubMed ID: 31427548
[TBL] [Abstract][Full Text] [Related]
18. Limited human epidermal growth factor receptor 2 discordance in metastatic breast cancer patients treated with trastuzumab, a population based study.
van Rooijen JM; de Munck L; de Graaf JC; Siesling S; de Vries EG; Boers JE
Eur J Cancer; 2014 Mar; 50(5):885-91. PubMed ID: 24491395
[TBL] [Abstract][Full Text] [Related]
19. HER2 immunohistochemistry significantly overestimates HER2 amplification in uterine papillary serous carcinomas.
Mentrikoski MJ; Stoler MH
Am J Surg Pathol; 2014 Jun; 38(6):844-51. PubMed ID: 24698965
[TBL] [Abstract][Full Text] [Related]
20. Comparison of four immunohistochemical tests and FISH for measuring HER2 expression in gastric carcinomas.
Cho EY; Srivastava A; Park K; Kim J; Lee MH; Do I; Lee J; Kim KM; Sohn TS; Kang WK; Kim S
Pathology; 2012 Apr; 44(3):216-20. PubMed ID: 22437741
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
